Why is $CTMX moving today? · SEC 8-K archive

$CTMX SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $CTMX: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $CTMX filing catalyst

Why did $CTMX trigger an AI stock catalyst alert?

$CTMX triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: CytomX Therapeutics Reports Q3 2026 Results: $348M Cash Extends Runway Into H2 2028. Key points: - Cash, equivalents, and short-term investments rose to $348.0M, extending operational runway into H2 2028. - Operating expenses rose to $25.2M (vs. $21.7M in Q3 2025); R&D expenses increased to $16.5M. - FDA granted Fast Track designation for Varseta-M in mCRC, with monotherapy Phase 1 update slated for January 2027.

How did $CTMX stock react after the SEC filing?

After the SEC 8-K for $CTMX, observed market reaction: T0 price $2.14. Past moves do not guarantee future results.

Where can I get real-time $CTMX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $CTMX via Telegram and the VIP Web Terminal from €10/month.

$CTMX

$CTMX – CytomX Therapeutics Reports Q3 2026 Results: $348M Cash Extends Runway Into H2 2028

CytomX Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $CTMX

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)

Cash, equivalents, and short-term investments rose to $348.0M, extending operational runway into H2 2028.
Operating expenses rose to $25.2M (vs. $21.7M in Q3 2025); R&D expenses increased to $16.5M.
FDA granted Fast Track designation for Varseta-M in mCRC, with monotherapy Phase 1 update slated for January 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →